while the QA Manager ensures that the formulations meet all quality and regulatory standards.

5. Procedure

5.1 Selecting Active Pharmaceutical Ingredient (API) for Capsule Fill

Ensure the correct API is selected for the capsule fill formulation:

1. API Characteristics
   1. Review the physicochemical properties of the API such as solubility, stability, and bioavailability to ensure its suitability for capsule fill formulations.
   2. Evaluate the API’s stability under various conditions, including temperature, humidity, and light, to ensure it will remain effective throughout the shelf life of the product.
2. API Compatibility
   1. Conduct compatibility studies between the selected API and excipients to ensure there are no interactions that might affect the stability or efficacy of the capsule.
   2. Use methods such as DSC, FTIR, or HPLC to identify potential incompatibilities between the API and excipients.

5.2 Selecting Excipients for Capsule Fill

Choose suitable excipients for the formulation based on the properties of the API:

1. Excipients Functionality
   1. Choose excipients such as fillers, binders, disintegrants, and lubricants that will support the API’s solubility, stability, and controlled release.
   2. Select excipients that comply with pharmacopoeial standards and are compatible with the API.
2. Excipients Compatibility
   1. Conduct compatibility testing for each excipient with the API to identify any chemical, physical, or functional incompatibilities.
   2. Use techniques like FTIR and HPLC to confirm the stability and compatibility of the excipients in the formulation.

5.3 Optimizing the Fill Formulation

Optimize the capsule fill formulation to achieve the desired quality attributes:

1. Formulation Development
   1. Mix the selected API with excipients to form a homogenous powder blend suitable for capsule filling.
   2. Adjust the amount of each excipient to achieve the desired capsule weight, dissolution rate, and stability.
2. Granulation Process
   1. If necessary, granulate the powder blend to improve its flowability and compressibility, ensuring a uniform fill in the capsule.
   2. Use wet or dry granulation methods depending on the characteristics of the powder blend and desired end product.
3. Powder Flow and Compressibility Testing
   1. Test the flow properties of the powder blend using bulk density, tapped density, and angle of repose to ensure consistent filling during capsule manufacturing.
   2. Test the compressibility of the powder blend if needed, using standard methods such as tablet hardness tests to assess its ability to form uniform capsules.

5.4 Capsule Fill Testing and Evaluation

Evaluate the capsule fill for various performance parameters:

1. Weight Uniformity
   1. Ensure the uniformity of capsule fill by measuring the weight of individual capsules and calculating the average weight and standard deviation.
   2. Ensure that the weight variation is within acceptable limits as per regulatory guidelines.
2. Content Uniformity
   1. Perform content uniformity tests to ensure the correct dosage of API in each capsule.
   2. Verify that the API content in each capsule falls within the specified range of the label claim.
3. Dissolution Testing
   1. Conduct dissolution tests on the capsule formulation to ensure that the API is released effectively and at the desired rate.
   2. Monitor the dissolution profile to confirm that it meets the required bioavailability specifications.

5.5 Stability Testing of Capsule Fill Formulation

Conduct stability studies to ensure the capsule fill formulation remains effective and stable over time:

1. Accelerated Stability Testing
   1. Subject the capsule formulation to accelerated stability testing under conditions of high temperature and humidity to predict its shelf life.
   2. Evaluate the physical, chemical, and microbiological properties of the formulation to determine its stability and any degradation over time.
2. Long-Term Stability Testing
   1. Conduct long-term stability studies to monitor the capsule formulation under normal storage conditions for an extended period.
   2. Analyze any changes in the appearance, dissolution, and potency of the formulation to confirm its stability over time.

5.6 Documentation and Record-Keeping

Ensure proper documentation of all formulation development activities:

1. Formulation Development Report
   1. Compile a detailed report of the formulation development process, including excipient selection, formulation parameters, testing results, and stability data.
   2. Ensure that all documentation is signed off by the formulation development team and reviewed by the QA team.
2. Record Retention
   1. Ensure that all records related to the capsule fill formulation, including testing and stability data, are securely stored and easily accessible for future reference and regulatory submissions.

6. Abbreviations

• SOP: Standard Operating Procedure
• API: Active Pharmaceutical Ingredient
• QA: Quality Assurance
• QC: Quality Control
• GMP: Good Manufacturing Practice
• HPLC: High-Performance Liquid Chromatography
• UV-Vis: Ultraviolet-Visible Spectroscopy

7. Documents

1. Formulation Development Report (Annexure-1)
2. Stability Testing Data (Annexure-2)
3. Capsule Fill Testing Report (Annexure-3)

8. References

• USP <711> – Dissolution Testing
• ICH Q1A (R2) – Stability Testing of New Drug Substances and Products
• FDA Guidance for Industry: Dosage Form Development

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Formulation Development Report

Date	Formulation Name	API	Excipient	Outcome
02/02/2025	Capsule A	API-123	Excip-456	Stable formulation

Annexure-2: Stability Testing Data

Date	Test Type	Result	Action Taken
02/02/2025	Accelerated Stability	No degradation observed	Proceed with further testing

Annexure-3: Capsule Fill Testing Report

Date	Test Type	Result	Action Taken
02/02/2025	Weight Uniformity	Pass	Continue formulation optimization

Revision History:

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
01/01/2024	1.0	Initial Version	New SOP Creation	QA Head
01/02/2025	2.0	Updated formulation development process	Standardization	QA Head